Chemical: Drug
methadone

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


1. FDA Label for methadone

Full label available at DailyMed

Genes and/or phenotypes found in this label


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for methadone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA CYP2B6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *4 N/A N/A N/A
No VIP available CA VA CYP2B6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *29 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *30 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *31 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *32 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *33 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *87 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *89 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *90 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *93 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *95 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *97 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *98 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C9 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1045280 NC_000017.10:g.4622638C>T, NC_000017.11:g.4719343C>T, NM_001257328.1:c.903C>T, NM_001257329.1:c.786+54C>T, NM_001257330.1:c.840C>T, NM_001257331.1:c.795C>T, NM_004313.3:c.840C>T, NM_199004.1:c.795C>T, NP_001244257.1:p.Ser301=, NP_001244259.1:p.Ser280=, NP_001244260.1:p.Ser265=, NP_004304.1:p.Ser280=, NP_945355.1:p.Ser265=, NR_047516.1:n.1037C>T, XM_006721520.1:c.264C>T, XM_006721521.1:c.264C>T, XM_011523858.1:c.933C>T, XM_011523859.1:c.888C>T, XP_006721583.1:p.Ser88=, XP_006721584.1:p.Ser88=, XP_011522160.1:p.Ser311=, XP_011522161.1:p.Ser296=, rs17850192, rs3185169, rs34094276, rs60822060
C > -
C > T
SNP
S301S
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1057868 NC_000007.13:g.75615006C>T, NC_000007.14:g.75985688C>T, NG_008930.1:g.75587C>T, NM_000941.2:c.1508C>T, NP_000932.3:p.Ala503Val, NW_003871064.1:g.3514924C>T, XM_005250459.1:c.1508C>T, XM_005250460.1:c.1205C>T, XM_005250461.1:c.932C>T, XM_005277600.1:c.1508C>T, XM_005277601.1:c.1205C>T, XM_005277602.1:c.932C>T, XP_005250516.1:p.Ala503Val, XP_005250517.1:p.Ala402Val, XP_005250518.1:p.Ala311Val, XP_005277657.1:p.Ala503Val, XP_005277658.1:p.Ala402Val, XP_005277659.1:p.Ala311Val, rs17840495, rs17846082, rs17859083, rs3198400, rs57699079
C > T
SNP
A503V
No VIP available No Clinical Annotations available VA
rs1076560 NC_000011.10:g.113412966C>A, NC_000011.9:g.113283688C>A, NG_008841.1:g.67314G>T, NM_000795.3:c.811-83G>T, NM_016574.3:c.724-83G>T, XM_005271425.1:c.811-83G>T, XM_005271426.1:c.808-83G>T, rs1800500
C > A
SNP
No VIP available CA VA
rs10835210 NC_000011.10:g.27674363C>A, NC_000011.9:g.27695910C>A, NG_011794.1:g.52696G>T, NM_001143805.1:c.-21-15778G>T, NM_001143806.1:c.-21-15778G>T, NM_001143807.1:c.-21-15778G>T, NM_001143808.1:c.-21-15778G>T, NM_001143809.1:c.67-15778G>T, NM_001143810.1:c.-58-21G>T, NM_001143811.1:c.-421-21G>T, NM_001143812.1:c.-21-15778G>T, NM_001143813.1:c.-21-15778G>T, NM_001143814.1:c.-128-15437G>T, NM_001709.4:c.-21-15778G>T, NM_170731.4:c.4-15778G>T, NM_170732.4:c.-21-15778G>T, NM_170733.3:c.-21-15778G>T, NM_170734.3:c.25-15778G>T, NR_002832.2:n.655-934C>A, NR_033312.1:n.586-1214C>A, NR_033313.1:n.585+15135C>A, NR_033314.1:n.655-2619C>A, NR_033315.1:n.586-2619C>A, XM_005253060.1:c.-79G>T, XM_011520280.1:c.-79G>T, XR_242807.1:n.507-1214C>A, XR_242808.1:n.504-1214C>A, XR_242809.1:n.282-1214C>A, rs17309902, rs60037280
C > A
SNP
No VIP available No Clinical Annotations available VA
rs11030118 NC_000011.10:g.27701516G>A, NC_000011.9:g.27723063G>A, NG_011794.1:g.25543C>T, NM_001143805.1:c.-22+19128C>T, NM_001143806.1:c.-22+18913C>T, NM_001143807.1:c.-22+17995C>T, NM_001143808.1:c.-557C>T, NM_001143809.1:c.-480C>T, NM_001143810.1:c.-604C>T, NM_001143811.1:c.-967C>T, NM_001143812.1:c.-862C>T, NM_001143813.1:c.-1356C>T, NM_001143814.1:c.-1481C>T, NM_001709.4:c.-1374C>T, NM_170731.4:c.3+19896C>T, NM_170732.4:c.-22+18830C>T, NM_170733.3:c.-241C>T, NM_170734.3:c.-2110C>T
G > A
SNP
No VIP available No Clinical Annotations available VA
rs11030119 NC_000011.10:g.27706555G>A, NC_000011.9:g.27728102G>A, NG_011794.1:g.20504C>T, NM_001143805.1:c.-22+14089C>T, NM_001143806.1:c.-22+13874C>T, NM_001143807.1:c.-22+12956C>T, NM_170731.4:c.3+14857C>T, NM_170732.4:c.-22+13791C>T, rs17244168, rs36211439, rs56442597, rs57712173, rs59667438
G > A
SNP
No VIP available No Clinical Annotations available VA
rs11188072 NC_000010.10:g.96519061C>T, NC_000010.11:g.94759304C>T, NG_008384.2:g.1599C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available CA VA
rs11940316 NC_000004.11:g.69961127T>C, NC_000004.12:g.69095409T>C, NM_001074.2:c.-1112T>C, XM_005265702.1:c.-26-3131T>C, XM_005265702.2:c.-26-3131T>C, XM_011532229.1:c.-1112T>C, XM_011532230.1:c.-1112T>C, XM_011532231.1:c.-26-3131T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs12233719 NC_000004.11:g.69962449G>T, NC_000004.12:g.69096731G>T, NM_001074.2:c.211G>T, NP_001065.2:p.Ala71Ser, XM_005265702.1:c.-26-1809G>T, XM_005265702.2:c.-26-1809G>T, XM_011532229.1:c.211G>T, XM_011532230.1:c.211G>T, XM_011532231.1:c.-26-1809G>T, XP_011530531.1:p.Ala71Ser, XP_011530532.1:p.Ala71Ser, rs52806684, rs58730779
G > T
SNP
A71S
No VIP available No Clinical Annotations available VA
rs12248560 NC_000010.10:g.96521657C>T, NC_000010.11:g.94761900C>T, NG_008384.2:g.4195C>T, NM_000769.2:c.-806C>T, rs117093607, rs17442305, rs17879736
C > A
C > T
SNP
No VIP available CA VA
rs1491850 NC_000011.10:g.27728178T>C, NC_000011.9:g.27749725T>C, rs17309937, rs59753623
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1714984 NC_000017.10:g.12617701A>G, NC_000017.11:g.12714384A>G, NG_012972.1:g.53495A>G, NM_001146312.2:c.122-1135A>G, NM_153604.3:c.122-1135A>G, XM_005256863.1:c.122-1135A>G, XM_005256864.1:c.-116-1135A>G, rs16946491, rs60539572
A > G
SNP
No VIP available CA VA
rs1799971 NC_000006.11:g.154360797A>G, NC_000006.12:g.154039662A>G, NG_021208.1:g.34162A>G, NM_000914.4:c.118A>G, NM_001008503.2:c.118A>G, NM_001008504.3:c.118A>G, NM_001008505.2:c.118A>G, NM_001145279.3:c.397A>G, NM_001145280.3:c.-11+28644A>G, NM_001145281.2:c.47+29103A>G, NM_001145282.2:c.118A>G, NM_001145283.2:c.118A>G, NM_001145284.3:c.118A>G, NM_001145285.2:c.118A>G, NM_001145286.2:c.118A>G, NM_001285522.1:c.118A>G, NM_001285523.1:c.118A>G, NM_001285524.1:c.397A>G, NP_000905.3:p.Asn40Asp, NP_001008503.2:p.Asn40Asp, NP_001008504.2:p.Asn40Asp, NP_001008505.2:p.Asn40Asp, NP_001138751.1:p.Asn133Asp, NP_001138754.1:p.Asn40Asp, NP_001138755.1:p.Asn40Asp, NP_001138756.1:p.Asn40Asp, NP_001138757.1:p.Asn40Asp, NP_001138758.1:p.Asn40Asp, NP_001272451.1:p.Asn40Asp, NP_001272452.1:p.Asn40Asp, NP_001272453.1:p.Asn133Asp, NR_104348.1:n.252A>G, NR_104349.1:n.252A>G, NR_104350.1:n.252A>G, NR_104351.1:n.252A>G, XM_005267002.1:c.304A>G, XM_006715497.2:c.304A>G, XM_011535849.1:c.397A>G, XP_005267059.1:p.Asn102Asp, XP_006715560.1:p.Asn102Asp, XP_011534151.1:p.Asn133Asp, XR_245534.1:n.304A>G, XR_245535.1:n.304A>G, XR_245536.1:n.304A>G, XR_245537.1:n.304A>G, rs17181017, rs52818856, rs61596185
A > -
A > G
SNP
N40D
No VIP available CA VA
rs1799978 NC_000011.10:g.113475629T>C, NC_000011.9:g.113346351T>C, NG_008841.1:g.4651A>G, NM_000795.3:c.-585A>G, NM_016574.3:c.-585A>G, XM_005271425.1:c.-32+29A>G, XR_948023.1:n.429A>G, rs386545565, rs4986916, rs61293607
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1800497 NC_000011.10:g.113400106G>A, NC_000011.9:g.113270828G>A, NG_012976.1:g.17316G>A, NM_178510.1:c.2137G>A, NP_848605.1:p.Glu713Lys, XM_011542736.1:c.2170G>A, XM_011542737.1:c.2140G>A, XM_011542738.1:c.1948G>A, XP_011541038.1:p.Glu724Lys, XP_011541039.1:p.Glu714Lys, XP_011541040.1:p.Glu650Lys, rs117686243, rs4134623, rs4245144, rs59538675
G > A
SNP
E713K
No VIP available No Clinical Annotations available VA
rs1861591 NC_000012.11:g.107416927T>C, NC_000012.12:g.107023149T>C, NM_004075.4:c.159-957A>G, XM_011537939.1:c.75-957A>G, rs59476315
T > C
SNP
No VIP available CA VA
rs1948308 NC_000009.11:g.87616257G>A, NC_000009.12:g.85001342G>A, NG_012201.2:g.337792G>A, NM_001018064.2:c.2125-18864G>A, NM_006180.4:c.2173-18864G>A, XM_005252001.1:c.2173-18864G>A, XM_005252002.1:c.2173-18864G>A, XM_005252003.1:c.2173-18864G>A, XM_005252004.1:c.2173-18864G>A, XM_005252005.1:c.2125-18864G>A, XM_011518718.1:c.2125-18864G>A, XM_011518719.1:c.2125-18864G>A, rs17535327, rs386550097, rs57669100
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1967554 NC_000011.10:g.27698012A>C, NC_000011.9:g.27719559A>C, NG_011794.1:g.29047T>G, NM_001143805.1:c.-22+22632T>G, NM_001143806.1:c.-22+22417T>G, NM_001143807.1:c.-22+21499T>G, NM_001143808.1:c.-22+2969T>G, NM_001143809.1:c.66+2959T>G, NM_001143810.1:c.-59+2959T>G, NM_001143811.1:c.-422+2959T>G, NM_001143812.1:c.-22+2664T>G, NM_001143813.1:c.-22+2170T>G, NM_001143814.1:c.-129+2152T>G, NM_001709.4:c.-22+2152T>G, NM_170731.4:c.3+23400T>G, NM_170732.4:c.-22+22334T>G, NM_170733.3:c.-22+3285T>G, NM_170734.3:c.24+1370T>G, NR_033312.1:n.1877A>C, NR_033313.1:n.1120A>C, NR_033315.1:n.1278A>C, rs57560974
A > C
SNP
No VIP available No Clinical Annotations available VA
rs2030324 NC_000011.10:g.27705368A>G, NC_000011.9:g.27726915A>G, NG_011794.1:g.21691T>C, NM_001143805.1:c.-22+15276T>C, NM_001143806.1:c.-22+15061T>C, NM_001143807.1:c.-22+14143T>C, NM_170731.4:c.3+16044T>C, NM_170732.4:c.-22+14978T>C, rs17244161, rs36211438
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs2036657 NC_000017.10:g.4625159G>A, NC_000017.11:g.4721864G>A, NM_001257328.1:c.*825G>A, NM_001257329.1:c.*931G>A, NM_001257330.1:c.*825G>A, NM_001257331.1:c.*825G>A, NM_004313.3:c.*825G>A, NM_199004.1:c.*825G>A, NR_047516.1:n.2252G>A, XM_006721520.1:c.*825G>A, XM_006721521.1:c.*825G>A, XM_011523858.1:c.*825G>A, XM_011523859.1:c.*825G>A, rs34772038, rs56655626
G > A
SNP
No VIP available CA VA
rs2070995 NC_000021.8:g.39086965T>C, NC_000021.9:g.37714662T>C, NG_029892.2:g.206732A>G, NM_002240.4:c.495A>G, NP_002231.1:p.Pro165=, XM_011529558.1:c.495A>G, XM_011529559.1:c.495A>G, XP_011527860.1:p.Pro165=, XP_011527861.1:p.Pro165=, XR_937707.1:n.-1255T>C, rs58872916
T > C
SNP
P165P
No VIP available CA VA
rs2075572 NC_000006.11:g.154412004G>C, NC_000006.12:g.154090869G>C, NG_021208.1:g.85369G>C, NM_000914.4:c.644-83G>C, NM_001008503.2:c.644-83G>C, NM_001008504.3:c.644-83G>C, NM_001008505.2:c.644-83G>C, NM_001145279.3:c.923-83G>C, NM_001145280.3:c.344-83G>C, NM_001145281.2:c.401-83G>C, NM_001145282.2:c.644-83G>C, NM_001145283.2:c.644-83G>C, NM_001145284.3:c.644-83G>C, NM_001145285.2:c.644-83G>C, NM_001145286.2:c.644-83G>C, NM_001145287.2:c.344-83G>C, NM_001285522.1:c.291-27814G>C, NM_001285523.1:c.644-83G>C, NM_001285524.1:c.923-83G>C, NM_001285526.1:c.344-83G>C, NM_001285527.1:c.344-83G>C, NM_001285528.1:c.344-83G>C, NR_104348.1:n.778-83G>C, NR_104349.1:n.778-83G>C, NR_104350.1:n.425-83G>C, NR_104351.1:n.778-83G>C, XM_005267002.1:c.830-83G>C, XM_005267003.1:c.344-83G>C, XM_011535849.1:c.923-83G>C, XM_011535850.1:c.437-83G>C, XM_011535851.1:c.344-83G>C, XM_011535852.1:c.344-83G>C, XM_011535853.1:c.344-83G>C, XM_011535854.1:c.344-83G>C, XM_011535855.1:c.344-83G>C, XM_011535856.1:c.344-83G>C, XM_011535857.1:c.344-83G>C, XM_011535858.1:c.344-83G>C, XM_011535859.1:c.344-83G>C, XM_011535860.1:c.344-83G>C, XM_011535861.1:c.344-83G>C, XM_011535862.1:c.344-83G>C, XR_245534.1:n.830-83G>C, XR_245535.1:n.830-83G>C, XR_245536.1:n.830-83G>C, XR_245537.1:n.477-83G>C, rs17174815, rs17210094, rs56680128
G > C
SNP
No VIP available CA VA
rs2120266 NC_000009.11:g.87456351G>A, NC_000009.12:g.84841436G>A, NG_012201.2:g.177886G>A, NM_001018064.2:c.1397-25807G>A, NM_001018065.2:c.1397-19604G>A, NM_001018066.2:c.1397-25807G>A, NM_006180.4:c.1397-19604G>A, XM_005252001.1:c.1397-19604G>A, XM_005252002.1:c.1397-19604G>A, XM_005252003.1:c.1397-19604G>A, XM_005252004.1:c.1397-19604G>A, XM_005252005.1:c.1397-25807G>A, XM_005252006.1:c.1397-19604G>A, XM_005252006.2:c.1397-19604G>A, XM_011518718.1:c.1397-25807G>A, XM_011518719.1:c.1397-25807G>A, XM_011518720.1:c.1397-25807G>A, rs58271572
G > A
SNP
No VIP available CA VA
rs2239622 NC_000001.10:g.115837709A>G, NC_000001.11:g.115295088A>G, NG_007944.1:g.48149T>C, NM_002506.2:c.-136-1338T>C, XM_006710663.2:c.-12-8281T>C, XM_006710665.2:c.-136-1338T>C, XM_011541518.1:c.30-1338T>C, rs11564885, rs17033636, rs386562190, rs52798500, rs61270451
A > G
SNP
No VIP available CA VA
rs2242480 NC_000007.13:g.99361466C>T, NC_000007.14:g.99763843C>T, NG_008421.1:g.25343G>A, NM_001202855.2:c.1023+12G>A, NM_017460.5:c.1026+12G>A, XM_011515841.1:c.1026+12G>A, XM_011515842.1:c.1023+12G>A, rs10364667, rs12721630, rs17161804, rs28969389, rs59491337, rs72494459, rs9655766
C > T
SNP
No VIP available CA VA
rs2246709 NC_000007.13:g.99365719A>G, NC_000007.14:g.99768096A>G, NG_008421.1:g.21090T>C, NM_001202855.2:c.670+258T>C, NM_017460.5:c.670+258T>C, XM_011515841.1:c.670+258T>C, XM_011515842.1:c.670+258T>C, rs56901335
A > G
SNP
No VIP available CA VA
rs2279343 NC_000019.10:g.41009358A>G, NC_000019.9:g.41515263A>G, NG_007929.1:g.23060A>G, NM_000767.4:c.785A>G, NP_000758.1:p.Lys262Arg, XM_005258569.1:c.785A>G, XM_005258569.3:c.785A>G, XM_005258570.1:c.785A>G, XM_005258571.1:c.365-2940A>G, XM_006723050.2:c.785A>G, XM_011526546.1:c.785A>G, XM_011526547.1:c.785A>G, XM_011526548.1:c.485-2940A>G, XM_011526549.1:c.194A>G, XM_011526550.1:c.365-2940A>G, XP_005258626.1:p.Lys262Arg, XP_005258627.1:p.Lys262Arg, XP_006723113.1:p.Lys262Arg, XP_011524848.1:p.Lys262Arg, XP_011524849.1:p.Lys262Arg, XP_011524851.1:p.Lys65Arg
A > G
SNP
K262R
No VIP available CA VA
rs2283265 NC_000011.10:g.113414814C>A, NC_000011.9:g.113285536C>A, NG_008841.1:g.65466G>T, NM_000795.3:c.724-353G>T, NM_016574.3:c.723+607G>T, XM_005271425.1:c.724-353G>T, XM_005271426.1:c.721-353G>T, rs2734840, rs60749713
C > A
SNP
No VIP available CA VA
rs2289658 NC_000009.11:g.87563370T>C, NC_000009.12:g.84948455T>C, NG_012201.2:g.284905T>C, NM_001018064.2:c.1717-7T>C, NM_006180.4:c.1765-7T>C, XM_005252001.1:c.1765-7T>C, XM_005252002.1:c.1765-7T>C, XM_005252003.1:c.1765-7T>C, XM_005252004.1:c.1765-7T>C, XM_005252005.1:c.1717-7T>C, XM_011518718.1:c.1717-7T>C, XM_011518719.1:c.1717-7T>C, rs386563821, rs58111962
T > C
SNP
No VIP available CA VA
rs2378676 NC_000009.11:g.87619423A>C, NC_000009.12:g.85004508A>C, NG_012201.2:g.340958A>C, NM_001018064.2:c.2125-15698A>C, NM_006180.4:c.2173-15698A>C, XM_005252001.1:c.2173-15698A>C, XM_005252002.1:c.2173-15698A>C, XM_005252003.1:c.2173-15698A>C, XM_005252004.1:c.2173-15698A>C, XM_005252005.1:c.2125-15698A>C, XM_011518718.1:c.2125-15698A>C, XM_011518719.1:c.2125-15698A>C, rs17450937, rs57144681
A > C
SNP
No VIP available CA VA
rs2760118 NC_000006.11:g.24503590C>T, NC_000006.12:g.24503362C>T, NG_008161.1:g.13394C>T, NM_001080.3:c.538C>T, NM_170740.1:c.538C>T, NP_001071.1:p.His180Tyr, NP_733936.1:p.His180Tyr, rs3765309, rs52829319, rs60953148
C > T
SNP
H180Y
No VIP available No Clinical Annotations available VA
rs28365062 NC_000004.11:g.69964271A>G, NC_000004.12:g.69098553A>G, NM_001074.2:c.735A>G, NP_001065.2:p.Thr245=, XM_005265702.1:c.-13A>G, XM_005265702.2:c.-13A>G, XM_011532229.1:c.735A>G, XM_011532230.1:c.735A>G, XM_011532231.1:c.-13A>G, XP_011530531.1:p.Thr245=, XP_011530532.1:p.Thr245=, rs58136729
A > G
SNP
T245T
No VIP available No Clinical Annotations available VA
rs3211371 NC_000019.10:g.41016810C>T, NC_000019.9:g.41522715C>T, NG_007929.1:g.30512C>T, NM_000767.4:c.1459C>T, NP_000758.1:p.Arg487Cys, XM_005258569.1:c.*48C>T, XM_005258569.3:c.*48C>T, XM_005258570.1:c.*214C>T, XM_005258571.1:c.859C>T, XM_006723050.2:c.*143C>T, XM_011526547.1:c.*214C>T, XM_011526548.1:c.979C>T, XM_011526549.1:c.868C>T, XM_011526550.1:c.859C>T, XP_005258628.1:p.Arg287Cys, XP_011524850.1:p.Arg327Cys, XP_011524851.1:p.Arg290Cys, XP_011524852.1:p.Arg287Cys, rs12721654, rs28399500, rs33995163, rs58951873
C > T
SNP
R487C
No VIP available No Clinical Annotations available VA
rs34230287 NC_000017.10:g.4613630C>T, NC_000017.11:g.4710335C>T, NM_001257328.1:c.-387C>T, NM_001257329.1:c.-387C>T, NM_001257330.1:c.-387C>T, NM_001257331.1:c.-387C>T, NM_004313.3:c.-387C>T, NM_199004.1:c.-387C>T, NR_047516.1:n.-159C>T, XM_006721520.1:c.-887C>T, XM_011523858.1:c.-439C>T, XM_011523859.1:c.-439C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs35599367 NC_000007.13:g.99366316G>A, NC_000007.14:g.99768693G>A, NG_008421.1:g.20493C>T, NM_001202855.2:c.522-191C>T, NM_017460.5:c.522-191C>T, XM_011515841.1:c.522-191C>T, XM_011515842.1:c.522-191C>T, rs45581939, rs62471940
G > A
SNP
No VIP available CA VA
rs3735451 NC_000007.13:g.99355975T>C, NC_000007.14:g.99758352T>C, NG_008421.1:g.30834A>G, NM_001202855.2:c.1414-124A>G, NM_017460.5:c.1417-124A>G, XM_011515841.1:c.1510-124A>G, XM_011515842.1:c.1507-124A>G, rs386585004, rs57555923
T > C
SNP
No VIP available CA VA
rs3745274 NC_000019.10:g.41006936G>T, NC_000019.9:g.41512841G>T, NG_007929.1:g.20638G>T, NM_000767.4:c.516G>T, NP_000758.1:p.Gln172His, XM_005258569.1:c.516G>T, XM_005258569.3:c.516G>T, XM_005258570.1:c.516G>T, XM_005258571.1:c.364+2490G>T, XM_006723050.2:c.516G>T, XM_011526546.1:c.516G>T, XM_011526547.1:c.516G>T, XM_011526548.1:c.484+2490G>T, XM_011526549.1:c.-75-1G>T, XM_011526550.1:c.364+2490G>T, XP_005258626.1:p.Gln172His, XP_005258627.1:p.Gln172His, XP_006723113.1:p.Gln172His, XP_011524848.1:p.Gln172His, XP_011524849.1:p.Gln172His, rs56308434, rs57685583
G > T
SNP
Q172H
No VIP available No Clinical Annotations available VA
rs3786047 NC_000017.10:g.4615098A>G, NC_000017.11:g.4711803A>G, NM_001257328.1:c.23+1059A>G, NM_001257329.1:c.23+1059A>G, NM_001257330.1:c.23+1059A>G, NM_001257331.1:c.23+1059A>G, NM_004313.3:c.23+1059A>G, NM_199004.1:c.23+1059A>G, NR_047516.1:n.251+1059A>G, XM_006721520.1:c.-478+1059A>G, XM_011523858.1:c.116+914A>G, XM_011523859.1:c.116+914A>G, rs12945492, rs36095488, rs60173149
A > G
SNP
No VIP available CA VA
rs4292394 NC_000004.11:g.69972949C>G, NC_000004.12:g.69107231C>G, NM_001074.2:c.1059C>G, NP_001065.2:p.Leu353=, XM_005265702.1:c.312C>G, XM_005265702.2:c.312C>G, XM_011532229.1:c.1059C>G, XM_011532230.1:c.1059C>G, XM_011532231.1:c.312C>G, XP_005265759.1:p.Leu104=, XP_011530531.1:p.Leu353=, XP_011530532.1:p.Leu353=, XP_011530533.1:p.Leu104=, rs61690735, rs76973289
C > G
SNP
L353L
No VIP available CA VA
rs4358872 NC_000009.11:g.87600969T>G, NC_000009.12:g.84986054T>G, NG_012201.2:g.322504T>G, NM_001018064.2:c.2124+30537T>G, NM_006180.4:c.2172+30537T>G, XM_005252001.1:c.2172+30537T>G, XM_005252002.1:c.2172+30537T>G, XM_005252003.1:c.2172+30537T>G, XM_005252004.1:c.2172+30537T>G, XM_005252005.1:c.2124+30537T>G, XM_011518718.1:c.2124+30537T>G, XM_011518719.1:c.2124+30537T>G
T > G
SNP
No VIP available No Clinical Annotations available VA
rs45482602 NC_000019.10:g.41009350C>A, NC_000019.9:g.41515255C>A, NG_007929.1:g.23052C>A, NM_000767.4:c.777C>A, NP_000758.1:p.Ser259Arg, XM_005258569.1:c.777C>A, XM_005258569.3:c.777C>A, XM_005258570.1:c.777C>A, XM_005258571.1:c.365-2948C>A, XM_006723050.2:c.777C>A, XM_011526546.1:c.777C>A, XM_011526547.1:c.777C>A, XM_011526548.1:c.485-2948C>A, XM_011526549.1:c.186C>A, XM_011526550.1:c.365-2948C>A, XP_005258626.1:p.Ser259Arg, XP_005258627.1:p.Ser259Arg, XP_006723113.1:p.Ser259Arg, XP_011524848.1:p.Ser259Arg, XP_011524849.1:p.Ser259Arg, XP_011524851.1:p.Ser62Arg, rs60810954
C > A
SNP
S259R
No VIP available CA VA
rs4554144 NC_000004.11:g.69960555C>T, NC_000004.12:g.69094837C>T, NM_001074.2:c.-1684C>T, XM_005265702.1:c.-26-3703C>T, XM_005265702.2:c.-26-3703C>T, XM_011532229.1:c.-1684C>T, XM_011532230.1:c.-1684C>T, XM_011532231.1:c.-26-3703C>T, rs6600881
C > T
SNP
No VIP available CA VA
rs4646437 NC_000007.13:g.99365083G>A, NC_000007.14:g.99767460G>A, NG_008421.1:g.21726C>T, NM_001202855.2:c.671-205C>T, NM_017460.5:c.671-202C>T, XM_011515841.1:c.671-202C>T, XM_011515842.1:c.671-205C>T, rs386594232, rs57997883
G > A
SNP
No VIP available CA VA
rs4646440 NC_000007.13:g.99360870G>A, NC_000007.14:g.99763247G>A, NG_008421.1:g.25939C>T, NM_001202855.2:c.1023+608C>T, NM_017460.5:c.1026+608C>T, XM_011515841.1:c.1026+608C>T, XM_011515842.1:c.1023+608C>T, rs386594233, rs56791612
G > A
SNP
No VIP available No Clinical Annotations available VA
rs4648317 NC_000011.10:g.113460810G>A, NC_000011.9:g.113331532G>A, NG_008841.1:g.19470C>T, NM_000795.3:c.-32+14266C>T, NM_016574.3:c.-32+14266C>T, XM_005271425.1:c.-32+14848C>T, rs386594403, rs57338776
G > A
SNP
No VIP available No Clinical Annotations available VA
rs4680 NC_000022.10:g.19951271G>A, NC_000022.11:g.19963748G>A, NG_011526.1:g.27009G>A, NM_000754.3:c.472G>A, NM_001135161.1:c.472G>A, NM_001135162.1:c.472G>A, NM_007310.2:c.322G>A, NP_000745.1:p.Val158Met, NP_001128633.1:p.Val158Met, NP_001128634.1:p.Val158Met, NP_009294.1:p.Val108Met, NR_039918.1:n.-5G>A, XM_005261229.1:c.472G>A, XM_011529885.1:c.586G>A, XM_011529886.1:c.586G>A, XM_011529887.1:c.472G>A, XM_011529888.1:c.472G>A, XM_011529889.1:c.472G>A, XM_011529890.1:c.472G>A, XM_011529891.1:c.472G>A, XP_005261286.1:p.Val158Met, XP_011528187.1:p.Val196Met, XP_011528188.1:p.Val196Met, XP_011528189.1:p.Val158Met, XP_011528190.1:p.Val158Met, XP_011528191.1:p.Val158Met, XP_011528192.1:p.Val158Met, XP_011528193.1:p.Val158Met, rs1131157, rs11544671, rs165688, rs17295216, rs17349704, rs17818178, rs17849308, rs17850006, rs2070104, rs3177905, rs3190784, rs3747070, rs58002978
G > A
SNP
V158M
No VIP available CA VA
rs4877900 NC_000009.11:g.87632318C>T, NC_000009.12:g.85017403C>T, NG_012201.2:g.353853C>T, NM_001018064.2:c.2125-2803C>T, NM_006180.4:c.2173-2803C>T, XM_005252001.1:c.2173-2803C>T, XM_005252002.1:c.2173-2803C>T, XM_005252003.1:c.2173-2803C>T, XM_005252004.1:c.2173-2803C>T, XM_005252005.1:c.2125-2803C>T, XM_011518718.1:c.2125-2803C>T, XM_011518719.1:c.2125-2803C>T, rs61447704
C > T
SNP
No VIP available No Clinical Annotations available VA
rs529520 NC_000001.10:g.29174946A>C, NC_000001.11:g.28848434A>C, NM_000911.3:c.228-10520A>C, rs17362661, rs386598235, rs61493073
A > C
SNP
No VIP available CA VA
rs5443 NC_000012.11:g.6954875C>T, NC_000012.12:g.6845711C>T, NG_009100.1:g.10501C>T, NM_001297571.1:c.822C>T, NM_002075.3:c.825C>T, NP_001284500.1:p.Ser274=, NP_002066.1:p.Ser275=, NW_003871083.2:g.47295C>T, XM_005253679.1:c.825C>T, XM_005253680.1:c.822C>T, XM_005253681.1:c.702-6C>T, XM_005277751.1:c.825C>T, XM_005277752.1:c.822C>T, XM_005277753.1:c.702-6C>T, XM_011520953.1:c.825C>T, XM_011520954.1:c.822C>T, XM_011521027.1:c.*1818G>A, XM_011521028.1:c.*1818G>A, XM_011521029.1:c.*2036G>A, XM_011521030.1:c.*1969G>A, XP_005253736.1:p.Ser275=, XP_005253737.1:p.Ser274=, XP_005277808.1:p.Ser275=, XP_005277809.1:p.Ser274=, XP_011519255.1:p.Ser275=, XP_011519256.1:p.Ser274=, rs2230334, rs3138516, rs57419337, rs6489738
C > T
SNP
S274S
No VIP available CA VA
rs558025 NC_000006.11:g.154441965A>G, NC_000006.12:g.154120830A>G, NG_021208.1:g.115330A>G, NM_000914.4:c.*2109A>G, NM_001008503.2:c.1164+29358A>G, NM_001145279.3:c.*2109A>G, NM_001145280.3:c.*2109A>G, NM_001145281.2:c.*2109A>G, NM_001145287.2:c.*2109A>G, NM_001285522.1:c.*2144A>G, NM_001285524.1:c.*2109A>G, NM_001285526.1:c.*2109A>G, NR_104348.1:n.3555A>G, NR_104350.1:n.3093A>G, XM_011535849.1:c.*293-191A>G, XM_011535859.1:c.*2109A>G, XM_011535860.1:c.*2109A>G, XM_011535861.1:c.*2109A>G, rs17181380, rs17276643, rs61090595
A > -
A > G
SNP
No VIP available No Clinical Annotations available VA
rs581111 NC_000001.10:g.29175373A>G, NC_000001.11:g.28848861A>G, NM_000911.3:c.228-10093A>G, rs386600012, rs59474409, rs9426304
A > G
SNP
No VIP available CA VA
rs6275 NC_000011.10:g.113412755A>G, NC_000011.9:g.113283477A>G, NG_008841.1:g.67525T>C, NM_000795.3:c.939T>C, NM_016574.3:c.852T>C, NP_000786.1:p.His313=, NP_057658.2:p.His284=, XM_005271425.1:c.939T>C, XM_005271426.1:c.936T>C, XP_005271482.1:p.His313=, XP_005271483.1:p.His312=, rs1130352, rs12791267, rs17115547, rs3189087, rs386602147, rs61689984
A > G
SNP
H313H
No VIP available CA VA
rs6277 NC_000011.10:g.113412737G>A, NC_000011.9:g.113283459G>A, NG_008841.1:g.67543C>T, NM_000795.3:c.957C>T, NM_016574.3:c.870C>T, NP_000786.1:p.Pro319=, NP_057658.2:p.Pro290=, XM_005271425.1:c.957C>T, XM_005271426.1:c.954C>T, XP_005271482.1:p.Pro319=, XP_005271483.1:p.Pro318=, rs1071576, rs1075651, rs17413837, rs3189090
G > A
SNP
P319P
No VIP available CA VA
rs6600879 NC_000004.11:g.69960387C>G, NC_000004.12:g.69094669C>G, NM_001074.2:c.-1852C>G, XM_005265702.1:c.-26-3871C>G, XM_005265702.2:c.-26-3871C>G, XM_011532229.1:c.-1852C>G, XM_011532230.1:c.-1852C>G, XM_011532231.1:c.-26-3871C>G, rs17381748
C > G
SNP
No VIP available CA VA
rs6600880 NC_000004.11:g.69960480T>A, NC_000004.12:g.69094762T>A, NM_001074.2:c.-1759T>A, XM_005265702.1:c.-26-3778T>A, XM_005265702.2:c.-26-3778T>A, XM_011532229.1:c.-1759T>A, XM_011532230.1:c.-1759T>A, XM_011532231.1:c.-26-3778T>A, rs17381762
T > A
SNP
No VIP available CA VA
rs6600893 NC_000004.11:g.69978901T>C, NC_000004.12:g.69113183T>C, NM_001074.2:c.*251+196T>C, NM_001074.2:c.*447T>C, XM_005265702.1:c.*447T>C, XM_005265702.2:c.*447T>C, XM_011532230.1:c.*707T>C, XM_011532231.1:c.*447T>C, rs58570437
T > C
SNP
No VIP available CA VA
rs7118900 NC_000011.10:g.113396099G>A, NC_000011.9:g.113266821G>A, NG_012976.1:g.13309G>A, NM_178510.1:c.715G>A, NP_848605.1:p.Ala239Thr, XM_011542736.1:c.745G>A, XM_011542737.1:c.715G>A, XM_011542738.1:c.523G>A, XP_011541038.1:p.Ala249Thr, XP_011541039.1:p.Ala239Thr, XP_011541040.1:p.Ala175Thr, rs535418425, rs59912012
G > A
SNP
A239T
No VIP available No Clinical Annotations available VA
rs7127507 NC_000011.10:g.27693337T>C, NC_000011.9:g.27714884T>C, NG_011794.1:g.33722A>G, NM_001143805.1:c.-22+27307A>G, NM_001143806.1:c.-22+27092A>G, NM_001143807.1:c.-22+26174A>G, NM_001143808.1:c.-22+7644A>G, NM_001143809.1:c.66+7634A>G, NM_001143810.1:c.-59+7634A>G, NM_001143811.1:c.-422+7634A>G, NM_001143812.1:c.-22+7339A>G, NM_001143813.1:c.-22+6845A>G, NM_001143814.1:c.-129+6827A>G, NM_001709.4:c.-22+6827A>G, NM_170731.4:c.3+28075A>G, NM_170732.4:c.-22+27009A>G, NM_170733.3:c.-22+7960A>G, NM_170734.3:c.24+6045A>G, NR_033312.1:n.1342+2197T>C, NR_033313.1:n.586-4141T>C, NR_033315.1:n.744-4141T>C, rs60889268, rs61439529, rs74233744
T > C
SNP
No VIP available CA VA
rs7438135 NC_000004.11:g.69961339G>A, NC_000004.12:g.69095621G>A, NM_001074.2:c.-900G>A, XM_005265702.1:c.-26-2919G>A, XM_005265702.2:c.-26-2919G>A, XM_011532229.1:c.-900G>A, XM_011532230.1:c.-900G>A, XM_011532231.1:c.-26-2919G>A
G > A
SNP
No VIP available CA VA
rs7439366 NC_000004.11:g.69964338T>C, NC_000004.12:g.69098620T>C, NM_001074.2:c.802T>C, NP_001065.2:p.Tyr268His, XM_005265702.1:c.55T>C, XM_005265702.2:c.55T>C, XM_011532229.1:c.802T>C, XM_011532230.1:c.802T>C, XM_011532231.1:c.55T>C, XP_005265759.1:p.Tyr19His, XP_011530531.1:p.Tyr268His, XP_011530532.1:p.Tyr268His, XP_011530533.1:p.Tyr19His, rs34924067, rs57980137
T > C
SNP
Y268H
No VIP available CA VA
rs7662029 NC_000004.11:g.69961912A>G, NC_000004.12:g.69096194A>G, NM_001074.2:c.-327A>G, XM_005265702.1:c.-26-2346A>G, XM_005265702.2:c.-26-2346A>G, XM_011532229.1:c.-327A>G, XM_011532230.1:c.-327A>G, XM_011532231.1:c.-26-2346A>G, rs17381776, rs17523009, rs58709065
A > G
SNP
No VIP available CA VA
rs7668258 NC_000004.11:g.69962078T>C, NC_000004.12:g.69096360T>C, NM_001074.2:c.-161T>C, XM_005265702.1:c.-26-2180T>C, XM_005265702.2:c.-26-2180T>C, XM_011532229.1:c.-161T>C, XM_011532230.1:c.-161T>C, XM_011532231.1:c.-26-2180T>C, rs17551675, rs60174701
T > C
SNP
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available CA VA
rs7934165 NC_000011.10:g.27710436G>A, NC_000011.9:g.27731983G>A, NG_011794.1:g.16623C>T, NM_001143805.1:c.-22+10208C>T, NM_001143806.1:c.-22+9993C>T, NM_001143807.1:c.-22+9075C>T, NM_170731.4:c.3+10976C>T, NM_170732.4:c.-22+9910C>T, rs58934494
G > A
SNP
No VIP available No Clinical Annotations available VA
rs9479757 NC_000006.11:g.154411344G>A, NC_000006.12:g.154090209G>A, NG_021208.1:g.84709G>A, NM_000914.4:c.643+31G>A, NM_001008503.2:c.643+31G>A, NM_001008504.3:c.643+31G>A, NM_001008505.2:c.643+31G>A, NM_001145279.3:c.922+31G>A, NM_001145280.3:c.343+31G>A, NM_001145281.2:c.400+31G>A, NM_001145282.2:c.643+31G>A, NM_001145283.2:c.643+31G>A, NM_001145284.3:c.643+31G>A, NM_001145285.2:c.643+31G>A, NM_001145286.2:c.643+31G>A, NM_001145287.2:c.343+31G>A, NM_001285522.1:c.291-28474G>A, NM_001285523.1:c.643+31G>A, NM_001285524.1:c.922+31G>A, NM_001285526.1:c.343+31G>A, NM_001285527.1:c.343+31G>A, NM_001285528.1:c.343+31G>A, NR_104348.1:n.777+31G>A, NR_104349.1:n.777+31G>A, NR_104350.1:n.425-743G>A, NR_104351.1:n.777+31G>A, XM_005267002.1:c.829+31G>A, XM_005267003.1:c.343+31G>A, XM_011535849.1:c.922+31G>A, XM_011535850.1:c.436+31G>A, XM_011535851.1:c.343+31G>A, XM_011535852.1:c.343+31G>A, XM_011535853.1:c.343+31G>A, XM_011535854.1:c.343+31G>A, XM_011535855.1:c.343+31G>A, XM_011535856.1:c.343+31G>A, XM_011535857.1:c.343+31G>A, XM_011535858.1:c.343+31G>A, XM_011535859.1:c.343+31G>A, XM_011535860.1:c.343+31G>A, XM_011535861.1:c.343+31G>A, XM_011535862.1:c.343+31G>A, XR_245534.1:n.829+31G>A, XR_245535.1:n.829+31G>A, XR_245536.1:n.829+31G>A, XR_245537.1:n.477-743G>A, rs17174808, rs60522300
G > A
SNP
No VIP available No Clinical Annotations available VA
rs988748 NC_000011.10:g.27703198C>G, NC_000011.9:g.27724745C>G, NG_011794.1:g.23861G>C, NM_001143805.1:c.-22+17446G>C, NM_001143806.1:c.-22+17231G>C, NM_001143807.1:c.-22+16313G>C, NM_170731.4:c.3+18214G>C, NM_170732.4:c.-22+17148G>C, NM_170733.3:c.-1923G>C, rs60852957
C > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • (+/-)-Methadone
  • (+/-)-Methadone hydrochloride
  • DL-Methadone hydrochloride
  • Methadon
  • Methadone HCL
  • Methadone hydrochloride
  • Phenadone hydrochloride
  • dl-Methadone
Trade Names
  • Adanon
  • Adanon hydrochloride
  • Adolan
  • Algidon
  • Algolysin
  • Algovetin
  • Althose hydrochloride
  • Amidon
  • Amidone
  • Biscuits
  • Butalgin
  • Depridol
  • Diaminon
  • Diaminon hydrochloride
  • Dollies
  • Dolly
  • Dolofin hydrochloride
  • Dolohepton
  • Dolophin
  • Dolophin hydrochloride
  • Dolophine
  • Dolophine HCL
  • Fenadon
  • Fenadone
  • Heptadon
  • Heptadone
  • Heptanon
  • Ketalgin
  • Ketalgin hydrochloride
  • Mecodin
  • Mephenon
  • Methadone HCL Intensol
  • Methadone M
  • Methadose
  • Methaquaione
  • Miadone
  • Moheptan
  • Phenadone
  • Physeptone
  • Polamidon
  • Polamidone
  • Tussol
  • Westadone
Brand Mixture Names
  • (+/-)-Tussal

PharmGKB Accession Id

PA450401

Type(s):

Drug

Description

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)

Source: Drug Bank

Indication

For the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Methadone is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.

Source: Drug Bank

Pharmacology

Methadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.

Source: Drug Bank

Food Interaction

Take without regard to meals. Avoid alcohol. Usually diluted in fruit juice.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine.

Source: Drug Bank

Protein Binding

In plasma, methadone is predominantly bound to alpha1-acid glycoprotein (85% to 90%).

Source: Drug Bank

Absorption

Well absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.

Source: Drug Bank

Half-Life

24-36 hours

Source: Drug Bank

Toxicity

In severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.

Source: Drug Bank

Clearance

  • 1.4 to 126 L/h

Source: Drug Bank

Route of Elimination

The elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion.
Unmetabolized methadone and its metabolites are excreted in urine to a variable degree.

Source: Drug Bank

Volume of Distribution

  • 1.0 to 8.0 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H27NO

Source: Drug Bank

Isomeric SMILES

CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c2ccccc2

Source: OpenEye

Canonical SMILES

CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1

Source: Drug Bank

Average Molecular Weight

309.4452

Source: Drug Bank

Monoisotopic Molecular Weight

309.209264491

Source: Drug Bank

SMILES

CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1

Source: Drug Bank

InChI String

InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
CHRNA10 (source: Drug Bank)
GRIN3A (source: Drug Bank)
OPRD1 (source: Drug Bank)
OPRM1 (source: Drug Bank)

Drug Interactions

Interaction Description
amprenavir - methadone The protease inhibitor decreases the effect of methadone (source: Drug Bank)
amprenavir - methadone The protease inhibitor, amprenavir, may decrease the effect of methadone. (source: Drug Bank)
carbamazepine - methadone Decreases levels of methadone (source: Drug Bank)
carbamazepine - methadone Decreases levels of methadone (source: Drug Bank)
cimetidine - methadone Increases the effect of the narcotic (source: Drug Bank)
cimetidine - methadone Increases the effect of the narcotic (source: Drug Bank)
fosamprenavir - methadone The protease inhibitor decreases the effect of methadone (source: Drug Bank)
fosamprenavir - methadone The protease inhibitor, fosamprenavir, may decrease the effect of methadone. (source: Drug Bank)
fosphenytoin - methadone The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - amobarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - amobarbital The barbiturate, amobarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - amprenavir The protease inhibitor decreases the effect of methadone (source: Drug Bank)
methadone - amprenavir The protease inhibitor, amprenavir, may decrease the effect of methadone. (source: Drug Bank)
methadone - aprobarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - aprobarbital The barbiturate, aprobarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - butabarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - butabarbital The barbiturate, butabarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - butalbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - butalbital The barbiturate, butalbital, decreases the effect of methadone. (source: Drug Bank)
methadone - butethal The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - butethal The barbiturate, butethal, decreases the effect of methadone. (source: Drug Bank)
methadone - carbamazepine Carbamazepine decreases levels of methadone (source: Drug Bank)
methadone - carbamazepine Carbamazepine decreases levels of methadone (source: Drug Bank)
methadone - cimetidine Cimetidine increases the effect of the narcotic (source: Drug Bank)
methadone - cimetidine Cimetidine increases the effect of the narcotic (source: Drug Bank)
methadone - efavirenz The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
methadone - efavirenz The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
methadone - ethotoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - ethotoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - fluvoxamine Fluvoxamine increases the effect and toxicity of methadone (source: Drug Bank)
methadone - fluvoxamine Fluvoxamine increases the effect and toxicity of methadone (source: Drug Bank)
methadone - fosamprenavir The protease inhibitor decreases the effect of methadone (source: Drug Bank)
methadone - fosamprenavir The protease inhibitor, fosamprenavir, may decrease the effect of methadone. (source: Drug Bank)
methadone - fosphenytoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - fosphenytoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - heptabarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - heptabarbital The barbiturate, heptabarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - hexobarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - hexobarbital The barbiturate, hexobarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - mephenytoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - mephenytoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - methohexital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - methohexital The barbiturate, methohexital, decreases the effect of methadone. (source: Drug Bank)
methadone - methylphenobarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - methylphenobarbital The barbiturate, methylphenobarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - naltrexone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
methadone - naltrexone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
methadone - nelfinavir Nelfinavir decreases the effect of methadone (source: Drug Bank)
methadone - nelfinavir Nelfinavir decreases the effect of methadone (source: Drug Bank)
methadone - nevirapine The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
methadone - nevirapine The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
methadone - pentobarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - pentobarbital The barbiturate, pentobarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - phenobarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - phenobarbital The barbiturate, phenobarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - phenytoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - phenytoin The hydantoin decreases the effect of methadone (source: Drug Bank)
methadone - primidone The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - primidone The barbiturate, primidone, decreases the effect of methadone. (source: Drug Bank)
methadone - quinidine The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - quinidine The barbiturate, quinidine barbiturate, decreases the effect of methadone. (source: Drug Bank)
methadone - rifabutin The rifamycin decreases the effect of methadone (source: Drug Bank)
methadone - rifabutin The rifamycin decreases the effect of methadone (source: Drug Bank)
methadone - rifampin The rifamycin decreases the effect of methadone (source: Drug Bank)
methadone - rifampin The rifamycin decreases the effect of methadone (source: Drug Bank)
methadone - rifapentine The rifamycin decreases the effect of methadone (source: Drug Bank)
methadone - rifapentine The rifamycin decreases the effect of methadone (source: Drug Bank)
methadone - ritonavir The protease inhibitor decreases the effect of methadone (source: Drug Bank)
methadone - ritonavir The protease inhibitor, ritonavir, may decrease the effect of methadone. (source: Drug Bank)
methadone - secobarbital The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - secobarbital The barbiturate, secobarbital, decreases the effect of methadone. (source: Drug Bank)
methadone - talbutal The barbiturate decreases the effect of methadone (source: Drug Bank)
methadone - talbutal The barbiturate, talbutal, decreases the effect of methadone. (source: Drug Bank)
methadone - zidovudine Methadone increases the effect and toxicity of zidovudine (source: Drug Bank)
methadone - zidovudine Methadone increases the effect and toxicity of zidovudine (source: Drug Bank)
naltrexone - methadone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
naltrexone - methadone Naltrexone may precipitate a withdrawal syndrome in opioid-dependent individuals (source: Drug Bank)
nelfinavir - methadone Nelfinavir decreases the effect of methadone (source: Drug Bank)
nelfinavir - methadone Nelfinavir decreases the effect of methadone (source: Drug Bank)
nevirapine - methadone The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
nevirapine - methadone The antiretroviral agent decreases the effect of methadone (source: Drug Bank)
phenobarbital - methadone The barbiturate decreases the effect of methadone (source: Drug Bank)
phenobarbital - methadone The barbiturate, phenobarbital, decreases the effect of methadone. (source: Drug Bank)
primidone - methadone The barbiturate decreases the effect of methadone (source: Drug Bank)
primidone - methadone The barbiturate, primidone, decreases the effect of methadone. (source: Drug Bank)
rifabutin - methadone The rifamycin decreases the effect of methadone (source: Drug Bank)
rifabutin - methadone The rifamycin decreases the effect of methadone (source: Drug Bank)
rifampin - methadone The rifamycin decreases the effect of methadone (source: Drug Bank)
rifampin - methadone The rifamycin decreases the effect of methadone (source: Drug Bank)
tamoxifen - methadone Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank)
tamoxifen - methadone Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank)
tamsulosin - methadone Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed. (source: Drug Bank)
tamsulosin - methadone Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed. (source: Drug Bank)
telithromycin - methadone Telithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank)
thiopental - methadone Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur. (source: Drug Bank)
thiopental - methadone Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur. (source: Drug Bank)
thiothixene - methadone May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
thiothixene - methadone May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
tipranavir - methadone Tipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal. (source: Drug Bank)
toremifene - methadone Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank)
tramadol - methadone Methadone may decrease the effect of Tramadol by decreasing active metabolite production. (source: Drug Bank)
trimipramine - methadone Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. (source: Drug Bank)
triprolidine - methadone The CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
triprolidine - methadone The CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
voriconazole - methadone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank)
vorinostat - methadone Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)
ziprasidone - methadone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank)
zuclopenthixol - methadone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to methadone: 60

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clinical pharmacokinetics. 2016. Csajka Chantal, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT). Drug and alcohol dependence. 2016. Zahari Zalina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). The American journal of drug and alcohol abuse. 2016. Zahari Zalina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C19 variants on methadone metabolism in vitro. Drug testing and analysis. 2016. Lan Tian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
In vitro assessment of 24 CYP2D6 allelic isoforms on the metabolism of methadone. Drug testing and analysis. 2016. Su Ying, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among Opioid-Dependent Patients on Methadone Maintenance Therapy. Pain and therapy. 2016. Zahari Zalina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology. 2015. Kharasch Evan D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. British journal of clinical pharmacology. 2014. Mouly S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Ethnic and genetic factors in methadone pharmacokinetics: A population pharmacokinetic study. Drug and alcohol dependence. 2014. Bart Gavin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. British journal of clinical pharmacology. 2014. Ke Alice Ban, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2014. Fonseca Francina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. Pharmacogenomics. 2014. Zhao Qin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. The pharmacogenomics journal. 2013. Clarke T-K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addiction biology. 2013. Levran Orna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA : the journal of the American Medical Association. 2013. Wachman Elisha M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013. Levran Orna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Pharmacogenetics and genomics. 2013. Dobrinas Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450-mediated drug metabolism in the brain. Journal of psychiatry & neuroscience : JPN. 2012. Miksys Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Reduced methadone clearance during aromatase inhibition. Journal of clinical psychopharmacology. 2012. Lu Wenjie Jessie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics and genomics. 2012. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics. 2012. Tian Jia-Ni, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics. 2011. Chen Chia-Hui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
beta-Arrestin2 influences the response to methadone in opioid-dependent patients. The pharmacogenomics journal. 2011. Oneda B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regulatory toxicology and pharmacology : RTP. 2011. Volpe Donna A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. Journal of clinical pharmacology. 2011. Zwisler Stine T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Nerve growth factor beta polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatment. The pharmacogenomics journal. 2011. Levran O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011. Meyer Markus R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series. Journal of medical case reports. 2011. Lu Wenjie J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clinical pharmacology and therapeutics. 2010. Bunten H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug metabolism and disposition: the biological fate of chemicals. 2010. Lu Wenjie Jessie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes. Molecular diagnosis & therapy. 2010. Fonseca Francina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size. Pharmacogenetics and genomics. 2010. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug metabolism and disposition: the biological fate of chemicals. 2009. Tolson Antonia H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009. Jannetto Paul J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and genomics. 2009. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenetics and genomics. 2009. Doehring Alexandra, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Intensity of opiate withdrawal in relation to the 825C>T polymorphism of the G-protein beta 3 subunit gene. Progress in neuro-psychopharmacology & biological psychiatry. 2009. Lieb B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Progress in neuro-psychopharmacology & biological psychiatry. 2008. Crettol Séverine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism. 2008. Wang Hongbing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. Genes, brain, and behavior. 2008. de Cid R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Human molecular genetics. 2008. Levran Orna, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clinical pharmacology and therapeutics. 2008. Campa D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic treatments for drug addiction: alcohol and opiates. The American journal of drug and alcohol abuse. 2008. Haile Colin N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical pharmacology and therapeutics. 2007. Eap C B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of opioids. Clinical pharmacology and therapeutics. 2007. Somogyi Andrew A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clinical pharmacology and therapeutics. 2006. Crettol Séverine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical pharmacology and therapeutics. 2006. Coller Janet K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clinical pharmacology and therapeutics. 2006. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clinical pharmacology and therapeutics. 2005. Crettol Séverine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug metabolism and drug interactions. 2006. Ejsing Thomas Broeng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
64019-553-67
DrugBank:
DB00333
ChEBI:
6807
KEGG Compound:
C07163
PubChem Compound:
4095
PubChem Substance:
149416
46505722
IUPHAR Ligand:
1605
Drugs Product Database (DPD):
2247698
ChemSpider:
3953
Therapeutic Targets Database:
DAP000267
FDA Drug Label at DailyMed:
5e70e915-b946-4a80-bcc6-3f49bc30f2f5
da0a54c6-8b53-4774-8c40-e615ac8d804d

Clinical Trials

These are trials that mention methadone and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.